New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:06 EDTARNAArena Pharmaceuticals initiates Phase 1b clinical trial of APD334
Arena Pharmaceuticals announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
06:47 EDTARNAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
06:45 EDTARNAArena says Eisai withdraws Belviq application in Canada
Subscribe for More Information
06:44 EDTARNAArena Pharmaceuticals says 'small number' of Belviq labels incomplete
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use